Form 4: IRADIMED CORP: Insider Sells Shares Under 10b5-1 Plan

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling over 7,500 shares through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who holds the positions of CEO, President, Chairman, Director, and is a 10% owner of IRADIMED CORPORATION, has reported transactions involving the sale of common stock.
• These sales occurred on April 13, 2026, and April 14, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
• The total number of shares sold across these transactions is 7,500.
• The weighted average sale prices ranged from $91.28 to $94.80 per share.
• Following these transactions, Susi's beneficial ownership of IRADIMED CORP common stock is reported as 2,210,000 shares, held indirectly through various trusts, including the Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider sales can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading, making the impact on sentiment limited.

Negatives

• Insider selling activity, particularly by a CEO and significant shareholder, can sometimes be interpreted negatively by the market, although this sale was conducted under a pre-established 10b5-1 plan.

Risks

• The filing does not explicitly mention any new or evolving risks.
• The primary risk associated with insider selling, even under a 10b5-1 plan, is the potential perception of reduced confidence in the company's future prospects by a key executive.

Future Outlook

The filing itself is a report of past transactions and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple transactions.
• The reporting person disclaims beneficial ownership of certain shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting sales under Rule 10b5-1 plans are common for executives. These plans allow insiders to sell shares at predetermined times or prices, providing a defense against insider trading allegations. The volume and timing of such sales can still influence market perception, especially if they represent a significant portion of an executive's holdings or occur during periods of company news.

Stakeholder Impact

• Shareholders: May interpret insider sales, even under a 10b5-1 plan, as a signal of reduced confidence, potentially impacting share price. However, the pre-planned nature of the sales may temper this reaction.
• Management: The filing confirms adherence to regulatory requirements for reporting insider transactions.
• Regulators: The filing serves as a transparent disclosure of beneficial ownership changes as mandated by the SEC.

Next Steps

• Continued monitoring of insider trading activity for IRADIMED CORP.
• Review of future SEC filings for any changes in beneficial ownership or new disclosures.

Key Dates

Keywords

IRADIMED CORP, IRMD, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, CEO, Director, Securities Exchange Act